

European Society for Blood and Marrow Transplantation

Rates of Upfront Autologous Stem Cell Transplantation (ASCT) in Newly **Diagnosed Multiple Myeloma (NDMM):** An updated report from the MRDR

Krystal Bergin^{1,2}, Cameron Wellard², Elizabeth Moore², Zoe McQuilten², Erica Wood², Hang Quach³, Hilary Blackwood⁴, Peter Mollee⁵, Joy Ho⁶, Simon He⁷, Jay Hocking⁸, Trish Walker⁹, Miles Prince¹⁰, Tracy King⁶, Bradley Augustson¹², Michael Dickinson¹³, Sundra Ramanathan¹⁴, James D'Rozario¹⁵, Ruth Spearing¹⁶, Noemi Horvath¹⁷, Teresa Leung¹⁸, Simon Harrison^{11,13,19}, Jane Estell²⁰, George Grigoriadis²¹, Luke Merriman²², Gaurav Srivastava²³, Magdalena Sobieraj-Teague²⁴, Anna Thompson²⁵, Tricia Wright²⁶ and Andrew Spencer^{1,2}

¹Alfred Health-Monash University, Melbourne, Australia; ²Department Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia; ³St. Vincent's Hospital, Melbourne, Australia; ⁴Middlemore Hospital, Middlemore, New Zealand; ⁵Princess Alexandra Hospital, Brisbane, Australia; ⁶Royal Prince Alfred Hospital, Sydney, Australia; ⁷Austin Health, Melbourne, Australia; ⁸Eastern Heath, Melbourne, Australia; ⁹Peninsula Health, Melbourne, Australia; ¹⁰Epworth Freemasons, Melbourne, Australia; ¹¹The Royal Melbourne Hospital, Melbourne, Australia; ¹²Sir Charles Gairdner Hospital, Perth, Australia; ¹³Peter MacCallum Cancer Centre, Melbourne, Australia; ¹⁴St George Hospital, Sydney; ¹⁵Canberra Hospital, Canberra, Australia; ¹⁶Christchurch Hospital, Christchurch, New Zealand, ¹⁷Royal Adelaide Hospital, Adelaide, Australia, ¹⁸Northern Health, Melbourne, Australia, ¹⁹Sir Peter MacCallum Dept of Oncology, Melbourne University, Australia; ²⁰Concord Repatriation General Hospital, Sydney, Australia; ²¹Monash Medical Centre, Clayton, Australia; ²²Nelson Hospital, Nelson, New Zealand; ²³Cabrini Hospital, Malvern, Australia; ²⁴Flinders Medical Centre, Adelaide, Australia; ²⁵Royal Hobart Hospital, Tasmania, Australia; ²⁶Latrobe Regional Hospital, Traralgon, Australia

Background

Despite clear evidence from both clinical trial and real world patient populations for the use of autologous stem cell transplantation (ASCT) as part of front-line therapy in newly diagnosed multiple myeloma (NDMM), utilisation rates are still lower than expected.¹⁻³ ASCT rates in patients considered age eligible have recently been reported as 43%, 55%, and 59% in published literature in the U.K., Australia, and the U.S. respectively.¹⁻³ In Australia and New Zealand patients are generally considered eligible for ASCT if they:¹

• are <75 years

- have a good performance status
- have no significant comorbidities/frailty

However, the biological fitness for ASCT is ultimately at the discretion of the treating physician.

Results con't

When patients were compared based on age group (<65 years vs patients 65-70 years)

- ASCT utilisation rates were higher in younger patients (82% in patients <65 years vs 55.8% in patients >65 years) see table 4
- Younger patients receiving an ASCT had an improved OS compared to older patients (68.2 months vs 60.9 months). However, ASCT recipients in both groups had a longer median OS than non-recipients (Median OS 68.2m vs 37.4m in patients <65y and 60.9m vs 43.1 in patients 65-70y in ASCT recipients and non-recipients respectively, see table 5) suggesting that ASCT is a beneficial therapy even in older patients.
- ASCT recipients had an improved progression-free survival (PFS) compared with non-recipients in the whole cohort (median PFS 33.5m (30.9-43.9) vs 25.4m (20.1-34.4) p<0.001) and this PFS

Methods

We conducted a retrospective review of adult patients registered on the Myeloma and Related Disease Registry (MRDR), a prospectively maintained database from 23 sites across Australia (20) and New Zealand (3). Patients aged <70 with NDMM from June, 2012 to Oct, 2016 with review data available at least 12 months post diagnosis were eligible for analysis. Baseline characteristics, therapies and outcomes were compared between recipients and non-recipients using chi square tests for categorical variables and rank sum tests for continuous variables. Kaplan Meier survival analysis was used to estimate time to disease progression and overall survival.

Results

364 of 489 patients received an ASCT (74.4%)- see table 1

Baseline characteristics, disease response to induction therapy and treatment are shown in tables 2 and 3

- Median time from diagnosis to first therapy was the same in both the ASCT and non-ASCT group (21 days)
- Median time to ASCT was 200.5 days.

Table 1: ASCT utilisation rates by age group

Patient Age (years)	All Patients	<50	50-55	55-60	60-65	65-70	p-value
Ν	489	70	64	94	123	138	
ASCT	364 (74.4%)	61 (87.1%)	54 (84.4%)	75 (79.8%)	97 (78.9%)	77 (55.8%)	<0.001

Table 2: Baseline Characteristics (All patients)

Baseline	Non-ASCT	ASCT	

Table 3: Therapy and Response Characteristics (All patients)

	merupy and nesponse endracteristics (1
	Non-ASCT	

benefit was still seen in older (65-70y) patients (median PFS 32.4 (29.4m-NR) vs 20.7 (17.6m-29.1m) p<0.001) in ASCT recipients and non-recipients respectively

Baseline characteristics and outcomes of these two groups are shown in tables 4 and 5 respectively.





Table 5: Overall Survival by age group

	All Patients		<65 years		65-70 years	
	No ASCT	ASCT	No ASCT	ASCT	No ASCT	ASCT
	n=125	n=364	(n=64)	(n=287)	(n=61)	(n=77)
ledian OS in	37.7 (31.4,	68.2 (58.8,	37.4 (30.2-	68.2 (58.8, NR)	43.1 (30.5, NR)	60.9 (44.1, NR)



Patients who did not receive an ASCT were:

- Older (median age 64.7 vs 59.6 years, p<0.001)
- Had poorer renal function (eGFR 69 vs 80 (p<0.001), Cr (91 vs 82 (p=0.013)) and higher ISS (p=0.005)
- Of patients with known data:
 - ISS stage predicted for ASCT utilisation (ISS 3 34.6% vs 24.2% in the non-ASCT vs **ASCT groups respectively**
 - Neither higher ECOG (≥2) or higher R-ISS (R-ISS 3) reached statistical significance for prediction of patients not receiving an ASCT (ECOG ≥2 24.4% vs 15.6%, p=0.077 and R-ISS 3 21% vs 10.9%, 0.051) in the non-ASCT versus ASCT groups respectively

Conclusions

No ASCT

www.ebmt.org

- ASCT

- ASCT is a highly effective therapy in MM but currently appears under-utilised in Australia/New Zealand.
- Further study to elucidate the reasons for this under-utilisation is indicated.
- Renal function and ISS stage at diagnosis appeared to be used as a guide to patient fitness for ASCT in this cohort while statistically ECOG status did not.
- Patients not receiving an ASCT were less likely to have been treated with bortezomib-containing induction (86% vs 94.2%, see table 3)
- Patients who did not receive an ASCT had a shorter progression free survival (PFS) (median 25.3 vs 33.5 months, p<0.001).
- Thalidomide-containing therapy was most frequently used for post ASCT maintenance (72%).

Contacts and Acknowledgments

Contact: sphpm-myeloma@monash.edu Website: mrdr.net.au

We would like to thank all MRDR collaborators and staff and the patients and their families

- Disease response to therapy (≥PR) was predictive of physician decision to undertake ASCT in all patients
- ASCT is utilised less frequently in older patients and not receiving an ASCT is associated with a poorer PFS and OS.
 - 56% of patients >65-70 years received an ASCT compared to 82% of patients <65 years (p<0.001).
- Consideration of an ASCT may benefit patients in this group
 - Further study with larger cohorts of patients are required to confirm if a true benefit of ASCT exists in patients >65 years

References

1. Wong Doo N, Coory M, White V, et al. Low uptake of upfront autologous transplantation for myeloma in a jurisdiction with universal health care coverage: a population-based patterns of care study in Australia. Clin Lymphoma Myeloma Leuk. 2014;14:61-67.

2. Morris TC, Velangi M, Jackson G, et al. Less than half of patients aged 65 years or under with myeloma proceed to transplantation: results of a two region population-based survey. British journal of haematology. 2005;128:510-512.

3. Nivison-Smith I, Simpson JM, Dodds AJ, Ma DD, Szer J, Bradstock KF. A population-based analysis of the effect of autologous hematopoietic cell transplant in the treatment of multiple myeloma. Leukemia & lymphoma. 2013;54:1671-1676.









